Stock losses escalated in the final hour as an increase in Treasury yields hit defensive names in the utilities and materials sectors.
Bristol-Myers, ServiceNow and Kimberly-Clark have posted major third quarter earnings surprises, but they are not the only one, says Jim Cramer.
Privately held Kaleo will re-release its EpiPen alternative early next year.
Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.
The company's share price has increased 1,500% since 2013.
Pro investors have been piling into these five stocks in the third quarter. Here's everything you need to know.
With a pair of Phase III trials coming up for its dermatological drug, Novan CEO Nate Stasko says the company is merely piercing the skin of its long-term potential.